Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
Tag: belantamab mafodotin
FDA committee backs GSK’s multiple myeloma drug
If approved, belantamab mafodotin will be a first-in-class anti-BCMA therapy for relapsed/refractory multiple myeloma
Read More
Positive multiple myeloma results for GSK
Belantamab mafodotin is on track for regulatory submission by the end of 2019.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
